Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
NCT06691243Phase 2Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cocaine use disorder (CUD) comparing Semaglutide with Placebo (2 arms). Primary endpoints: Safety of semaglutide at 16 weeks and Tolerability of semaglutide at 16 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT06691243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691243.